NMRD Stock Overview
A medical technology company, manufactures continuous glucose monitoring system in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Nemaura Medical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.064 |
| 52 Week Low | US$0.000001 |
| Beta | -107.21 |
| 1 Month Change | -50.00% |
| 3 Month Change | 0% |
| 1 Year Change | -99.70% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Nemaura Medical GAAP EPS of -$0.17
Aug 15Nemaura Medical GAAP EPS of -$0.59 misses by $0.12, revenue of $0.51M
Jun 30Nemaura Medical: Opportunity In The Consumer-Centered Continuous Glucose Monitoring Market
Mar 10Nemaura Medical (NASDAQ:NMRD) Has Debt But No Earnings; Should You Worry?
Nov 17
Nemaura Medical: From Believer To Skeptic
Sep 20Nemaura: Wearable Monitoring Patches For Type-2 Diabetics Could Be An Inspired Move
Jul 02How Much Of Nemaura Medical Inc. (NASDAQ:NMRD) Do Insiders Own?
Dec 22
Shareholder Returns
| NMRD | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 0.8% |
| 1Y | -99.7% | 6.0% | 7.2% |
Return vs Industry: NMRD underperformed the US Medical Equipment industry which returned 7.2% over the past year.
Return vs Market: NMRD underperformed the US Market which returned 8.2% over the past year.
Price Volatility
| NMRD volatility | |
|---|---|
| NMRD Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 9.2% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: NMRD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine NMRD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | n/a | Faz Chowdhury | nemauramedical.com |
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs.
Nemaura Medical Inc. Fundamentals Summary
| NMRD fundamental statistics | |
|---|---|
| Market cap | US$4.04k |
| Earnings (TTM) | -US$10.65m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs NMRD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NMRD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$1.48m |
| Gross Profit | -US$1.48m |
| Other Expenses | US$9.17m |
| Earnings | -US$10.65m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -110.2% |
How did NMRD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/06 06:37 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nemaura Medical Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Constantine Davides | D. Boral Capital LLC. |
| Yi Chen | H.C. Wainwright & Co. |